[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$alpmy](/topic/$alpmy) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "H.C. Wainwright reiterated $CRBP Buy/$40 after Corbus presented Phase 1/2 data of CRB-701 at ESMO 2025 and hosted a panel of KOL to discuss CRB-701 in HNSCC. $PFE $MRUS H.C. Wainwright said: Expanding upon data presented at ASCO-GU the readout reaffirms CRB-701 as a best-in-class ADC for safety when compared to competitors Padcev and Tivdak (PFE; not rated) and demonstrate a promising ORR across multiple tumor types in heavily pretreated patients (3.6 mg/kg dose: XXXX% in HNSCC XXXX% in cervical cancer and XXXX% in mUC). Not only is the reported ORR comparable to benchmark petosemtamab (MRUS;" [X Link](https://x.com/Quantumup1/status/1980231098454958121) [@Quantumup1](/creator/x/Quantumup1) 2025-10-20T11:14Z 3850 followers, 4469 engagements "$PFE Pfizer and Japan's $ALPMY Astellas announced on Saturday that their drug Padcev when combined with Merck's Keytruda reduces the risk of tumor recurrence progression or death in bladder cancer patients" [X Link](https://x.com/ovtlyr/status/1980218390922055773) [@ovtlyr](/creator/x/ovtlyr) 2025-10-20T10:23Z XXX followers, XXX engagements "$PFE $ALPMY Pfizer and Astellas announced final Phase X results showing XTANDI (enzalutamide) + leuprolide cut the risk of death by XX% compared to leuprolide alone in men with advanced non-metastatic prostate cancer (high-risk biochemical recurrence). 8-year survival: XXXX% vs XXXX% First androgen-receptor inhibitor combo to show overall survival benefit in this setting Results presented at #ESMO2025 and published in The New England Journal of Medicine" [X Link](https://x.com/allday_stocks/status/1979946210342428873) [@allday_stocks](/creator/x/allday_stocks) 2025-10-19T16:22Z 1544 followers, XXX engagements "$PFE $MRK $ALPMY ESMO 2025: Pfizer Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients" [X Link](https://x.com/MarcJacksonLA/status/1979945513211617382) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-19T16:19Z 7590 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"H.C. Wainwright reiterated $CRBP Buy/$40 after Corbus presented Phase 1/2 data of CRB-701 at ESMO 2025 and hosted a panel of KOL to discuss CRB-701 in HNSCC. $PFE $MRUS H.C. Wainwright said: Expanding upon data presented at ASCO-GU the readout reaffirms CRB-701 as a best-in-class ADC for safety when compared to competitors Padcev and Tivdak (PFE; not rated) and demonstrate a promising ORR across multiple tumor types in heavily pretreated patients (3.6 mg/kg dose: XXXX% in HNSCC XXXX% in cervical cancer and XXXX% in mUC). Not only is the reported ORR comparable to benchmark petosemtamab (MRUS;"
X Link @Quantumup1 2025-10-20T11:14Z 3850 followers, 4469 engagements
"$PFE Pfizer and Japan's $ALPMY Astellas announced on Saturday that their drug Padcev when combined with Merck's Keytruda reduces the risk of tumor recurrence progression or death in bladder cancer patients"
X Link @ovtlyr 2025-10-20T10:23Z XXX followers, XXX engagements
"$PFE $ALPMY Pfizer and Astellas announced final Phase X results showing XTANDI (enzalutamide) + leuprolide cut the risk of death by XX% compared to leuprolide alone in men with advanced non-metastatic prostate cancer (high-risk biochemical recurrence). 8-year survival: XXXX% vs XXXX% First androgen-receptor inhibitor combo to show overall survival benefit in this setting Results presented at #ESMO2025 and published in The New England Journal of Medicine"
X Link @allday_stocks 2025-10-19T16:22Z 1544 followers, XXX engagements
"$PFE $MRK $ALPMY ESMO 2025: Pfizer Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients"
X Link @MarcJacksonLA 2025-10-19T16:19Z 7590 followers, XXX engagements
/topic/$alpmy/posts